Bixiye
Upcoming policies effective November 2_ 2020.pdf
Natiijooyinka Raadinta
Soo bandhiga 2341 - 2350 ee natiijooyinka 3701
Bixiye
QP96-20 Medical Drug Update for New to Market Inclisiran
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP97-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia Factor VIII PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP98-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Fintepla® (fenfluramine) PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP101-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) Criteria: Dojolvi™ PA
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
P50R1-20 Update: eviCore is Changing Prior Authorization Guidelines used to Review Durable Medical Equipment (DME), Home Health Care (HHC), and Post-Acute Care (PAC) Services for Medicare Advantage Subscribers
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2020
Bixiye
P65-20 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2020
Bixiye
P70-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates—Effective November 2, 2020
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2020
Bixiye
P67-20 Radiation Oncology Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2020